Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gadolinium oxide nanoparticles (Gd2O3 NPs) are inorganic nanomaterials utilized as high-performance contrast agents for magnetic resonance imaging (MRI). They leverage the high paramagnetic moment of gadolinium ions (Gd3+) to shorten the T1 relaxation time of surrounding water protons, thereby enhancing signal intensity in T1-weighted images. In clinical research, these nanoparticles are being explored for various applications, including targeted imaging of tumors and as components in medical devices to improve visibility under MRI guidance. Specifically, research at The University of Texas at Austin has evaluated their use in polyimide resins to enhance the visibility of microneedles used in convection-enhanced delivery (CED) systems for treating glioblastoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gadolinium oxide nanoparticles.